Clinical trials: Mild Neurocognitive Disorder
Alzheimer Disease
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of…
- Trial name
- NCT00895895
- Testing
- SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg
- Where
- 96 sites in United States, Argentina and 11 more
- Volunteers
- 526 people
- Sponsor
- Pfizer
Alzheimer's Disease, Cognitive Impairment
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients…
- Trial name
- NCT00814346
- Testing
- EGb761®
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- Ipsen
Alzheimer's Disease
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo…
- Trial name
- NCT00930059
- Testing
- PF-04447943
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Dementia, Mild, Depression
Decision Making Tool for Firearm Storage
This is a one-arm pilot study testing the feasibility and acceptability of a decision aid about safe firearm storage.
- Trial name
- NCT06382194
- Testing
- Decision aid
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Mild Cognitive Impairment
ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment
The Advance Care Planning Group Visit intervention is a new intervention that uses the strengths of group visits to promote advance care planning conversations and documentation.
- Trial name
- ENACT-aMCI (NCT03711396)
- Testing
- Advance Care Planning Group Visits
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Alzheimer's Disease
An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311
To evaluate the long-term safety, tolerability and potential efficacy, patients who previously participated in V203-AD study (NCT02551809) will be eligible to participate in the extension study and will receive 3 or 5 doses of…
- Trial name
- NCT03531710
- Testing
- UB-311
- Where
- 4 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- United Neuroscience Ltd.
Alzheimer Disease
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03443973
- Testing
- Gantenerumab
- Where
- 155 sites in United States, Argentina and 17 more
- Volunteers
- 975 people
- Sponsor
- Hoffmann-La Roche
Tetraplegia, Hypothermia
Body Temperature in Persons With Tetraplegia When Exposed to Cold
The ability to maintain normal body core temperature (Tcore = 98.6°F) is impaired in persons with tetraplegia. Despite the known challenges to the ability of persons with spinal cord injury (SCI) to maintain Tcore, and the…
- Conditions
- Tetraplegia, Hypothermia, Mild Cognitive Impairment
- Trial name
- NCT01822535
- Testing
- Midodrine hydrochloride
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Alzheimer Disease
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets
This study assessed the Hr QoL (Health related Quality of life) of subjects with mild to moderate AD, who received ARICEPT under usual clinical practice.
- Trial name
- QUEST (NCT01089582)
- Testing
- No intervention
- Where
- 29 sites in Greece
- Volunteers
- 628 people
- Sponsor
- Pfizer
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose.
- Trial name
- NCT00428090
- Testing
- Rosiglitazone
- Where
- 138 sites in United States, Austria and 18 more
- Volunteers
- 862 people
- Sponsor
- GlaxoSmithKline
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease.
- Trial name
- NCT02503501
- Testing
- Insulin glulisine
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- HealthPartners Institute
Depression, Mild Cognitive Impairment
Combination Treatment Study for Memory Impairment and Depression
Patients presenting with depression (DEP) and cognitive impairment (CI), represent a unique, understudied population that is difficult to diagnose, treat and estimate prognosis.
- Trial name
- DEP-CI (NCT01658228)
- Testing
- Donepezil, Citalopram, Venlafaxine
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- New York State Psychiatric Institute
Mild Cognitive Impairment, Cognitive Impairment
Study of Nasal Insulin to Fight Forgetfulness - Device Study
The SNIFF Device study will involve using a device to administer insulin through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body.
- Trial name
- NCT03857321
- Testing
- Insulin, intranasal nebulizer-like device
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Mild to Moderate Alzheimer's Disease
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
To evaluate the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE) in mild to moderate Alzheimer's…
- Trial name
- ENA1stepswitch (NCT02703636)
- Testing
- Rivastigmine Patch
- Where
- 19 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
- Trial name
- NCT04468347
- Testing
- Flortaucipir F18, Brain PET scan
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Depression Mild, Depressive Disorder, Major
Cognitive Fitness for Depression in Older Adults
This research is being done to determine if computerized administered cognitive fitness activities will improve thinking and depression in older depressed adults who are being treated with antidepressants.
- Conditions
- Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
- Trial name
- NCT04790630
- Testing
- Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- UConn Health
Alzheimer's Disease
Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00381238
- Testing
- rosiglitazone
- Where
- 7 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Dementia, Mild Cognitive Impairment
Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia
The AMOR-Kentucky study will examine the impact of a pharmacist-physician patient-centered medication therapy management deprescribing intervention to address inappropriate medication use in patients with cognitive impairment in…
- Trial name
- AMOR-KY (NCT05078437)
- Testing
- Medication therapy management
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Daniela Moga
Alzheimer's Disease
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
- Trial name
- NCT02916056
- Testing
- Azeliragon 5mg
- Where
- 71 sites in United States, Canada
- Volunteers
- 297 people
- Sponsor
- vTv Therapeutics
Dementia, Alzheimer Disease
Digital Interventions in Neuro-Rehabilitation: Gotcha!
Aims and background Everyone forgets the names of people they should know at times. Having dementia makes this problem worse. People with dementia have told expressed they forget the names of people they care about and this can…
- Conditions
- Dementia, Alzheimer Disease, Anomia
- Trial name
- NCT04570215
- Testing
- Gotcha! Therapy application, Gotcha Therapy application: Maintenance
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London